Drug discovery and development company e-Therapeutics (LON:ETX) revealed it has started a second phase I clinical trial of its anti-cancer drug ETS2101.
It comes after an investigator-led phase I study of ETS2101 in brain cancer that began in San Diego, California in June.
“The initiation of a second trial with ETS2101 reflects the growing momentum in our clinical development programme,” said e-Therapeutics chief executive Professor Malcolm Young.
“We hope that the promising preclinical data supporting this drug will ultimately translate into benefits for patients and look forward to seeing the first findings from cancer trials later this year.”
The company said up to 45 patients with a variety of solid tumours will take part in the trial, which is to take place at St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.
Like the brain cancer study, the UK trial has a dose-escalating design, which means groups of patients will receive successively higher doses of the ETS2101.
While the primary objectives are to test the safety of the drug and pick out an appropriate dose for phase II development, secondary objectives include assessing the drug’s activity and how it spreads in the body.